Targeting a ceramide double bond improves insulin resistance and hepatic steatosis

Ceramides in focus Excess calorie intake can ultimately lead to a metabolic syndrome that interferes with fat or lipid metabolism. There are many different types of lipids, and it has been widely debated which are the true culprits underlying metabolic disorders. Chaurasia et al. report that ceramides are the major contributor to insulin resistance and fatty liver disease (see the Perspective by Kusminski and Scherer). This appears to be caused by the enzyme dihydroceramide desaturase 1 (DES1), which is normally involved in ceramide production by inserting a double bond into the backbone of the molecule. In mice fed a high-fat diet, deletion of DES1 improved glucose and lipid metabolism. Science, this issue p. 386; see also p. 319 Deletion of dihydroceramide desaturase 1 (DES1) resolves insulin resistance and fatty liver in mice. Ceramides contribute to the lipotoxicity that underlies diabetes, hepatic steatosis, and heart disease. By genetically engineering mice, we deleted the enzyme dihydroceramide desaturase 1 (DES1), which normally inserts a conserved double bond into the backbone of ceramides and other predominant sphingolipids. Ablation of DES1 from whole animals or tissue-specific deletion in the liver and/or adipose tissue resolved hepatic steatosis and insulin resistance in mice caused by leptin deficiency or obesogenic diets. Mechanistic studies revealed ceramide actions that promoted lipid uptake and storage and impaired glucose utilization, none of which could be recapitulated by (dihydro)ceramides that lacked the critical double bond. These studies suggest that inhibition of DES1 may provide a means of treating hepatic steatosis and metabolic disorders.

[1]  L. Sandirasegarane,et al.  Ceramide-induced Inhibition of Akt Is Mediated through Protein Kinase Cζ , 2002, The Journal of Biological Chemistry.

[2]  M. Birnbaum,et al.  Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. , 2007, Cell metabolism.

[3]  S. Summers,et al.  Does This Schlank Make Me Look Fat? , 2018, Trends in Endocrinology & Metabolism.

[4]  Scott D Covey,et al.  Cholesterol depletion inhibits fatty acid uptake without affecting CD36 or caveolin-1 distribution in adipocytes. , 2007, Biochemical and biophysical research communications.

[5]  S. Summers,et al.  Ceramides – Lipotoxic Inducers of Metabolic Disorders , 2015, Trends in Endocrinology & Metabolism.

[6]  F. Liu,et al.  Regulation of Insulin Action by Ceramide , 2004, Journal of Biological Chemistry.

[7]  P. Meikle,et al.  Adipocyte Ceramides Regulate Subcutaneous Adipose Browning, Inflammation, and Metabolism. , 2016, Cell metabolism.

[8]  L. Almasy,et al.  PLASMA DIHYDROCERAMIDE SPECIES ASSOCIATE WITH WAIST CIRCUMFERENCE IN MEXICAN AMERICAN FAMILIES , 2013, Obesity.

[9]  J. Hamilton,et al.  Fatty acid transport and metabolism in HepG2 cells. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[10]  U. Klein,et al.  Transcriptional control of adipose lipid handling by IRF4. , 2011, Cell metabolism.

[11]  J. Hamilton,et al.  Fatty acids are rapidly delivered to and extracted from membranes by methyl-β-cyclodextrin , 2010, Journal of Lipid Research.

[12]  S. Summers,et al.  Ceramides as modulators of cellular and whole-body metabolism. , 2011, The Journal of clinical investigation.

[13]  P. Ferré,et al.  Plasma Membrane Subdomain Compartmentalization Contributes to Distinct Mechanisms of Ceramide Action on Insulin Signaling , 2009, Diabetes.

[14]  S. Summers,et al.  Dihydroceramides: From Bit Players to Lead Actors* , 2015, The Journal of Biological Chemistry.

[15]  N. Dimopoulos,et al.  Targeting of PKCzeta and PKB to caveolin-enriched microdomains represents a crucial step underpinning the disruption in PKB-directed signalling by ceramide. , 2008, The Biochemical journal.

[16]  J. Goldstein,et al.  Selective versus total insulin resistance: a pathogenic paradox. , 2008, Cell metabolism.

[17]  Rebecca A. Johnson,et al.  Fatty acid transport , 2001, Journal of Molecular Neuroscience.

[18]  C. Kahn,et al.  Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. , 2006, Cell metabolism.

[19]  V. Salomaa,et al.  Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[20]  B. Bergman,et al.  Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. , 2015, American journal of physiology. Endocrinology and metabolism.

[21]  Rhoderick E. Brown,et al.  The 4,5-double bond of ceramide regulates its dipole potential, elastic properties, and packing behavior. , 2004, Biophysical journal.

[22]  D. Siscovick,et al.  Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study , 2018, Diabetes.

[23]  I. Albert,et al.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. , 2015, The Journal of clinical investigation.

[24]  Yechezkel Barenholz,et al.  Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. , 2004, Sub-cellular biochemistry.

[25]  M. Erion,et al.  Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus. , 2016, American journal of physiology. Endocrinology and metabolism.

[26]  D. Accili,et al.  Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity , 2015, Molecular metabolism.

[27]  Adam Kowalczyk,et al.  Plasma Lipid Profiling Shows Similar Associations with Prediabetes and Type 2 Diabetes , 2013, PloS one.

[28]  R. Bauer,et al.  Ceramide Synthase Schlank Is a Transcriptional Regulator Adapting Gene Expression to Energy Requirements. , 2018, Cell reports.

[29]  Paul Verkade,et al.  Long-chain fatty acid uptake into adipocytes depends on lipid raft function. , 2004, Biochemistry.

[30]  Honglin Zhou,et al.  Regulation of Insulin-Stimulated Glucose Transporter GLUT4 Translocation and Akt Kinase Activity by Ceramide , 1998, Molecular and Cellular Biology.

[31]  Marju Orho-Melander,et al.  Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars , 2018, Diabetes Care.

[32]  Kim Ekroos,et al.  Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol , 2016, European heart journal.

[33]  M. Orešič,et al.  Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .

[34]  J. McDonald,et al.  Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis. , 2015, Cell metabolism.

[35]  S. Summers,et al.  Could Ceramides Become the New Cholesterol? , 2018, Cell metabolism.

[36]  J. Hamilton,et al.  Fast Diffusion of Very Long Chain Saturated Fatty Acids across a Bilayer Membrane and Their Rapid Extraction by Cyclodextrins , 2009, The Journal of Biological Chemistry.

[37]  R. Bishop,et al.  Molecular mechanism for lateral lipid diffusion between the outer membrane external leaflet and a beta-barrel hydrocarbon ruler. , 2009, Biochemistry.

[38]  A. Suzuki,et al.  DES2 protein is responsible for phytoceramide biosynthesis in the mouse small intestine. , 2004, The Biochemical journal.

[39]  J. Hamilton,et al.  The enigmatic membrane fatty acid transporter CD36: New insights into fatty acid binding and their effects on uptake of oxidized LDL. , 2016, Prostaglandins, leukotrienes, and essential fatty acids.

[40]  Ioannis Xenarios,et al.  Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans. , 2017, Cell reports.

[41]  T. Vogt,et al.  AAV8-Mediated Long-Term Expression of Human LCAT Significantly Improves Lipid Profiles in hCETP;Ldlr+/− Mice , 2011, Journal of cardiovascular translational research.

[42]  P. Serruys,et al.  Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients[S] , 2018, Journal of Lipid Research.

[43]  W. Stremmel,et al.  Uptake of long chain fatty acids is regulated by dynamic interaction of FAT/CD36 with cholesterol/sphingolipid enriched microdomains (lipid rafts) , 2008, BMC Cell Biology.

[44]  J. Hamilton,et al.  CD36 enhances fatty acid uptake by increasing the rate of intracellular esterification but not transport across the plasma membrane. , 2013, Biochemistry.

[45]  J. Brozinick,et al.  Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet , 2012, International Journal of Obesity.

[46]  É. Hajduch,et al.  Ceramide Disables 3-Phosphoinositide Binding to the Pleckstrin Homology Domain of Protein Kinase B (PKB)/Akt by a PKCζ-Dependent Mechanism , 2003, Molecular and Cellular Biology.